Medexus Pharmaceuticals Inc.
MEDXF
$1.77
-$0.01-0.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.42% | -53.23% | -66.61% | -117.53% | 153.84% |
| Total Depreciation and Amortization | 5.94% | -0.47% | -3.59% | -4.52% | -4.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.45% | -3.11% | -4.06% | 65.45% | -66.76% |
| Change in Net Operating Assets | -10.66% | 194.93% | 160.16% | 115.34% | 132.08% |
| Cash from Operations | 11.42% | 67.83% | 234.39% | 1,395.98% | 1,475.08% |
| Capital Expenditure | -127.59% | -5.63% | 23.94% | 15.25% | 13.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 53.60% | -35.02% | -73.58% | -136.35% | -237.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,613.66% | -1,586.96% | 28.71% | 28.71% | 90.97% |
| Cash from Investing | -23.14% | -137.32% | -55.97% | -102.09% | -26.96% |
| Total Debt Issued | -34.53% | -41.33% | -47.33% | -50.41% | 210.69% |
| Total Debt Repaid | 79.39% | -86.83% | -91.59% | -77.92% | -32,188.73% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.84% | -6.47% | 6.80% | 1.80% | -11.88% |
| Cash from Financing | 0.87% | -3,068.89% | -779.15% | -459.84% | -533.33% |
| Foreign Exchange rate Adjustments | -448.42% | 254.55% | -77.55% | 98.94% | 153.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.51% | -227.14% | -186.24% | -356.11% | -255.70% |